kabutan
N225

65,269.33

-1.70%

TOPIX

4,050.33

-1.83%

USDJPY

153.85

-0.34%

Kabutan Concierge Closed Beta - Apply now

HEALIOS rebounds after obtaining manufacturing and marketing approval license for regenerative medicine products

Tue Sep 1, 2026 1:08 pm JST Catalyst

HEALIOS K.K. <4593> rebounded after announcing after market close on the 31st that it received a Manufacturing and Marketing Approval License for Regenerative Medicine Products from the Governor of Hyogo Prefecture, dated the 24th. The market welcomed the news.

HEALIOS has been preparing to file for approval of its somatic stem cell regenerative medicine product HLCM051 as a treatment for acute respiratory distress syndrome (ARDS). With this license, the company will be able to manufacture and market the product once its development pipeline receives approval, including conditional and time-limited approval.

The company previously announced obtaining the same license in April 2022, but reacquired it following a revision of its product development plans.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.